**Supplemental information**

*Supplementary Figure 1-* DEHP at 40 µg/mL causes no observable cytotoxicity. **(A)** Phase contrast images of the HeLa cells, iBECs, Caco-2 cells, and HL-1s treated with 40 µg/mL DEHP or equivalent volume DMSO (vehicle) for 24 hours (Scale bars = 200 µm) **(B)** Trypan blue viability assay on HeLa cells treated with vehicle or DEHP for 24 hours prior to infecting with enhanced green fluorescent protein-expressing-CVB (EGFP-CVB) at a multiplicity of infection (MOI) of 0.001 or mock-infecting for 24 hours (Student’s t-test; n=3 per group. Error bars represent standard deviation).

*Supplementary Figure 2-* DEHP enhances CVB infection of HL-1 cells. **(A)** Fluorescence microscopy detecting EGFP expression in HL-1 cells treated with 40 µg/mL DEHP or equivalent volume vehicle for 24 hours prior to infecting with EGFP-CVB at an MOI of 1 for 24 hours (scale bars= 200 µm). **(B)** Western blot detecting viral capsid protein VP1 in lysates from cells in **A**. Ponceau S (Pon S) stain is shown below. The densitometric quantification of VP1 is shown to the right. **(C)** Viral plaque assays enumerating infectious viral titers in tissue culture media from cells in **A** (Student’s t-test; n=3 per group; \*\*p<0.01, \*\*\*p<0.001. Error bars represent standard deviation).